SCHEMBL1799019

SCHEMBL1799019

O=C(c1ccc(F)cc1)N1CCC2(CC1)N[C@@H](Cc1ccccc1)C(=O)N2Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
CHRM2 P08172 1/20 0.45
CHRM3 P20309 1/20 0.45
CYP2D6 P10635 3/20 0.44
MAPK1 P28482 1/20 0.44
TSHR P16473 2/20 0.43
KMT2A Q03164 1/20 0.43
HSD11B1 P28845 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
MAPK10 P53779 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1799641 0.99 RIPK1 (0.46) RIPK1CHRM2CHRM3CYP2D6MAPK1
SCHEMBL1800862 0.95 CXCR3 (0.46) RIPK1CHRM2CHRM3HSD11B1KDM4E
SCHEMBL2937011 0.95 CXCR3 (0.46) RIPK1CHRM2CHRM3HSD11B1KDM4E
SCHEMBL2934126 0.95 CXCR3 (0.46) RIPK1CHRM2CHRM3HSD11B1KDM4E
Hydrochloric Acid SCHEMBL1801174 0.94 CXCR3 (0.45) RIPK1CHRM2CHRM3HSD11B1KDM4E
SCHEMBL2937853 0.91 RIPK1 (0.47) RIPK1CHRM2CHRM3CYP2D6TSHR
SCHEMBL1801302 0.91 RIPK1 (0.47) RIPK1CHRM2CHRM3CYP2D6TSHR
SCHEMBL4000263 0.91 RIPK1 (0.47) RIPK1CHRM2CHRM3CYP2D6TSHR
Hydrochloric Acid SCHEMBL1800383 0.90 RIPK1 (0.47) RIPK1CHRM2CHRM3CYP2D6TSHR
SCHEMBL1803464 0.90 KMT2A (0.48) RIPK1CHRM2CHRM3CYP2D6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 RIPK1 3818/4885CHRM2 3853/4885CHRM3 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.